Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 4/20 | 0.81 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.81 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | BACE1 | P56817 | 1/20 | 0.59 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.57 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.56 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3216529 | 1.00 | LTA4H (0.81) | LTA4HPTGS2PTGS1KDM4EALDH1A1 | |
| SCHEMBL3209576 | 0.99 | LTA4H (0.83) | LTA4HPTGS2PTGS1KDM4EALDH1A1 | |
| SCHEMBL13202242 | 0.93 | LTA4H (0.72) | LTA4HPTGS2PTGS1KDM4EALDH1A1 | |
| SCHEMBL18788213 | 0.92 | LTA4H (0.73) | LTA4HPTGS2PTGS1KDM4EALDH1A1 | |
| SCHEMBL491779 | 0.90 | HRH3 (0.72) | LTA4HPTGS2KDM4EALDH1A1HRH3 | |
| SCHEMBL5857234 | 0.88 | HRH3 (0.70) | LTA4HPTGS2KDM4EALDH1A1HRH3 | |
| SCHEMBL3207509 | 0.88 | LTA4H (0.68) | LTA4HPTGS2PTGS1KDM4EALDH1A1 | |
| SCHEMBL1961763 | 0.87 | LTA4H (0.67) | LTA4HPTGS2PTGS1KDM4EALDH1A1 | |
| SCHEMBL29848488 | 0.87 | LTA4H (0.67) | LTA4HPTGS2PTGS1KDM4EALDH1A1 | |
| SCHEMBL27853350 | 0.87 | LTA4H (0.67) | LTA4HPTGS2PTGS1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048891-A1 | METASUBSTITUTED THIAZOLIDINONES, THEIR MANUFACTURE AND USE AS A DRUG | SCHULZE KLAUSE | 2010-02-25 | — | — | US | disclosed |
| US-20100048891-A1 | METASUBSTITUTED THIAZOLIDINONES, THEIR MANUFACTURE AND USE AS A DRUG | SCHULZE KLAUSE | 2010-02-25 | — | — | US | disclosed |
| US-20100048891-A1 | METASUBSTITUTED THIAZOLIDINONES, THEIR MANUFACTURE AND USE AS A DRUG | SCHULZE KLAUSE | 2010-02-25 | — | — | US | disclosed |
| US-20070015759-A1 | Metasubstituted thiazolidinones, their manufacture and use as a drug | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-18 | — | — | US | disclosed |
| US-20070015759-A1 | Metasubstituted thiazolidinones, their manufacture and use as a drug | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048891-A1 | METASUBSTITUTED THIAZOLIDINONES, THEIR MANUFACTURE AND USE AS A DRUG | PLK2, PDXK, PLK4 | LTA4H 2174/4885PTGS2 1116/4885PTGS1 1007/4885 |
| US-20070015759-A1 | Metasubstituted thiazolidinones, their manufacture and use as a drug | PLK4, PDXK, PLK2 | LTA4H 1982/4885PTGS2 996/4885PTGS1 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.